Cardiac Magnetic Resonance Guidance of Implantable Cardioverter Defibrillator Implantation in Non-ischemic Dilated Cardiomyopathy — CMR-ICD  

Non-ischemic Dilated Cardiomyopathy Clinical Trial

Official title: Randomized Controlled, Multi-centre Trial of Cardiac Magnetic Resonance Guidance of Implantable Cardioverter Defibrillator Implantation in Non-ischemic Dilated Cardiomyopathy

Status Recruiting

Clinical Trial Summary

Patients with diagnostic CMR images for assessment of LGE/fibrosis and evidence/presence of non-ischaemic myocardial fibrosis/scar will be randomized to the following treatment groups in a 1:1 ratio: ICD group or Optimal HF care group.

Clinical Trial Description

The primary objective of this study is to evaluate the hypothesis that implantable cardioverter defibrillator (ICD) therapy would decrease the risk of death from any cause in comparison to optimal heart failure (HF) care without ICD insertion in patients with NIDCM, left ventricular ejection fraction (LVEF) ≤35% and presence of myocardial fibrosis on cardiac magnetic resonance (CMR) imaging. ;

Related Conditions & MeSH terms

• Cardiomyopathies
• Cardiomyopathy, Dilated
• Non-ischemic Dilated Cardiomyopathy

• NCT number: NCT04558723
• Study type: Interventional
• Source: University of Luebeck
• Contact: Ingo Eitel, Prof. Dr.
• Phone: +49 451 500 44501
• Email: ingo.eitel@uksh.de
• Status: Recruiting
• Phase: N/A
• Start date: January 14, 2021
• Completion date: November 2027